CoChat
Sign Up
Cited by 107Reproductive Health and ContraceptionLipoproteins and Cardiovascular HealthEstrogen and related hormone effects

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive: A Randomized, Open-Label, Single-Centre Study

Junge, Wolfgang, Mellinger, Uwe, Parke, Susanne, Serrani, Marco·2011·Clinical Drug Investigation
DOI 10.2165/11590220-000000000-00000
Open this paper in CoChat — free account

Abstract

Background and objective The hormonal components of combined oral contraceptives (COCs) have various metabolic and haemostatic effects. The objective of this study was to compare the metabolic and haemostatic effects of a novel COC comprising estradiol valerate/dienogest (E(2)V/DNG) with ethinylestradiol/levonorgestrel (EE/LNG).Methods In a randomized, open-label study conducted in Germany over seven cycles, healthy women aged 18-50 years received E(2)V/DNG (E(2)V 3 mg on days 1-2, E(2)V 2 mg/DNG 2 mg on days 3-7, E(2)V 2 mg/DNG 3 mg on days 8-24, E(2)V 1 mg on days 25-26, placebo on days 27-28; n = 30) or EE/LNG (EE 0.03 mg/LNG 0.05 mg on days 1-6, EE 0.04 mg/LNG 0.075 mg on days 7-11, EE 0.03 mg/LNG 0.125 mg on days 12-21, placebo on days 22-28; n = 28). The primary variables were the mean intraindividual relative changes from baseline to cycle 7 in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels. Changes in other lipid parameters, haemostatic parameters, sex hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), carbohydrate metabolism parameters, blood pressure and body weight were also assessed.Results Mean ± SD HDL cholesterol increased by 7.9% ± 21.8% with E(2)V/DNG and decreased by 2.3% ± 14.4% with EE/LNG. Mean ± SD LDL cholesterol decreased by 6.5% ± 15.9% with E(2)V/DNG and by 3.0% ± 17.4% with EE/LNG. Mean ± SD prothrombin fragment 1 + 2 and D-dimer levels remained essentially unchanged in the E(2)V/DNG group (-0.6% ± 30.3% and -2.1% ± 43.5%, respectively), but increased in the EE/LNG group (by 117.3% ± 358.0% and 62.9% ± 99.5%, respectively). Changes in other hepatic-induced parameters (SHBG, CBG) and carbohydrate metabolism were generally less pronounced with E(2)V/DNG versus EE/LNG. Body weight and blood pressure remained stable throughout the study in both treatment groups. Both formulations were well tolerated, with no serious adverse events reported.Conclusion E(2)V/DNG had a minimal impact on metabolic and haemostatic parameters, and a more favourable effect than EE/LNG on lipid markers.Trial registration ClinicalTrials.gov Identifier: NCT00185224.

Overview

Integrity signals

Registry

Crossref · 10.2165/11590220-000000000-00000

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 7

  1. Hirvonen, 1990, Advances Contraception, 6, 248
  2. Kivinen, 1996, Eur J Contracept Reprod Health Care, 1, 183
  3. Helgason, 1982 Suppl, Acta Obstet Gynecol Scand, 107, 1
  4. Oelkers, 1995 Jun, J Clin Endocrinol Metab, 80, 1816, 10.1210/jc.80.6.1816 · DOI
  5. Oettel, 1999, Drugs Today, 35, 3
  6. Parke, 2008, Obstet Gynecol, 111, 15S
  7. Parke, 2008, Eur J Contracept Reprod Health Care, 13, 94

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Junge, W., Mellinger, U., Parke, S., & Serrani, M.
Affiliations
Bayer (Germany) (DE)
Corresponding author
Parke, Susanne
Venue
Clinical Drug Investigation
Publisher
Springer Science and Business Media LLC
Published
2011-08
Volume
31
Issue
8
Pages
573-584
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
DOI
10.2165/11590220-000000000-00000
OpenAlex
W194649371
Cited by
107
References
44
Citations by year
2026: 7 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 3 · 2014: 10 · 2013: 8 · 2012: 10
FWCI
9.11
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Drug Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
combined oral contraceptives, lipid metabolism, HDL cholesterol, LDL cholesterol, sex hormone-binding globulin, corticosteroid-binding globulin, carbohydrate metabolism, blood pressure, body weight, prothrombin fragment 1+2, D-dimer, hemostasis
MeSH terms
Adult, Contraceptives, Oral, Combined, Drug Combinations, Estradiol, Ethinyl Estradiol, Female, Glucose Tolerance Test, Hematologic Tests, Hemostasis, Humans, Lipids, Middle Aged, Nandrolone, Thyroid Function Tests, Treatment Outcome, Levonorgestrel, Carbohydrate Metabolism, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review